neutral
1h agoBioMarin Acquires Amicus Therapeutics in $4.8 Billion Deal to Expand Rare Disease Portfolio
BioMarin Pharmaceutical announced it will acquire Amicus Therapeutics for $4.8 billion, enhancing its rare disease drug portfolio. The acquisition adds two key drugs, Galafold and Pombiliti + Opfolda, which treat Fabry disease and Pompe disease, respectively. Amicus’ stock jumped more than 30% to nearly match the takeover price of $14.50 per share. BioMarin expects the deal to immediately accelerate its sales and boost earnings, while also securing rights to the potential treatment for kidney disease, DMX-200.
Explore:Mutual Fund Categories
neutral
1h agoBioMarin Acquires Amicus Therapeutics in $4.8 Billion Deal to Expand Rare Disease Portfolio
BioMarin Pharmaceutical announced it will acquire Amicus Therapeutics for $4.8 billion, enhancing its rare disease drug portfolio. The acquisition adds two key drugs, Galafold and Pombiliti + Opfolda, which treat Fabry disease and Pompe disease, respectively. Amicus’ stock jumped more than 30% to nearly match the takeover price of $14.50 per share. BioMarin expects the deal to immediately accelerate its sales and boost earnings, while also securing rights to the potential treatment for kidney disease, DMX-200.
Explore:Mutual Fund Categories
Recently
1 min read
76 words
BioMarin acquires Amicus Therapeutics for $4.8 billion, adding rare disease drugs Galafold and Pombiliti + Opfolda to its portfolio and expanding its enzyme therapy business.
BioMarin Pharmaceutical announced it will acquire Amicus Therapeutics for $4.8 billion, enhancing its rare disease drug portfolio. The acquisition adds two key drugs, Galafold and Pombiliti + Opfolda, which treat Fabry disease and Pompe disease, respectively. Amicus’ stock jumped more than 30% to nearly match the takeover price of $14.50 per share. BioMarin expects the deal to immediately accelerate its sales and boost earnings, while also securing rights to the potential treatment for kidney disease, DMX-200.
BioMarin Pharmaceutical announced it will acquire Amicus Therapeutics for $4.8 billion, enhancing its rare disease drug portfolio. The acquisition adds two key drugs, Galafold and Pombiliti + Opfolda, which treat Fabry disease and Pompe disease, respectively. Amicus’ stock jumped more than 30% to nearly match the takeover price of $14.50 per share. BioMarin expects the deal to immediately accelerate its sales and boost earnings, while also securing rights to the potential treatment for kidney disease, DMX-200.
Dec 20, 2025 • 04:25